Cargando…

Angiotensin Converting Enzyme 2 May Mediate Disease Severity In COVID-19

Detalles Bibliográficos
Autores principales:	Gue, Ying Xuan, Kanji, Rahim, Markides, Vias, Gorog, Diana Adrienne
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Inc. 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7282749/ https://www.ncbi.nlm.nih.gov/pubmed/32636018 http://dx.doi.org/10.1016/j.amjcard.2020.06.002

Ejemplares similares

MI with Non-obstructive Coronary Artery Presenting with STEMI: A Review of Incidence, Aetiology, Assessment and Treatment
por: Gue, Ying X, et al.
Publicado: (2020)

Fibrinolysis in Platelet Thrombi
por: Kanji, Rahim, et al.
Publicado: (2021)

Development of a novel risk score to predict mortality in patients admitted to hospital with COVID-19
por: Gue, Ying X., et al.
Publicado: (2020)

Author Correction: Development of a novel risk score to predict mortality in patients admitted to hospital with COVID-19
por: Gue, Ying X., et al.
Publicado: (2021)

Angiotensin Converting Enzymes
por: Wong, Marty K.S.
Publicado: (2016)

Angiotensin converting enzyme
por: Wong, Marty Kwok-Shing
Publicado: (2021)

Angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARBs) may be safe for COVID-19 patients
por: Wang, Wenjun, et al.
Publicado: (2021)

Thrombotic complications in 2928 patients with COVID-19 treated in intensive care: a systematic review
por: Jenner, William J., et al.
Publicado: (2021)

Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may be harmful in patients with diabetes during COVID-19 pandemic
por: Cure, Erkan, et al.
Publicado: (2020)

The host’s angiotensin-converting enzyme polymorphism may explain epidemiological findings in COVID-19 infections
por: Delanghe, Joris R., et al.
Publicado: (2020)

Circulating angiotensin converting enzyme 2 and COVID-19
por: Leowattana, Wattana, et al.
Publicado: (2022)

Angiotensin-Converting Enzyme-2
por: Clarke, Nicola E., et al.
Publicado: (2013)

Angiotensin-converting enzyme activity and inhibition in dogs with cardiac disease and an angiotensin-converting enzyme polymorphism
por: Meurs, Kathryn M, et al.
Publicado: (2017)

Dietary Potassium Downregulates Angiotensin-I Converting Enzyme, Renin, and Angiotensin Converting Enzyme 2
por: Vio, Carlos P., et al.
Publicado: (2020)

Effects of angiotensin receptor blockers and angiotensin-converting enzyme inhibitors on COVID-19
por: Li, Xiao-Long, et al.
Publicado: (2021)

Commentary on “angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may be harmful in patients with diabetes during COVID-19 pandemic”
por: Ferrario, Carlos M.
Publicado: (2020)

Angiotensin-Converting Enzyme 2 and Antihypertensives (Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors) in Coronavirus Disease 2019
por: Sanchis-Gomar, Fabian, et al.
Publicado: (2020)

Angiotensin converting enzyme inhibitors and angiotensin receptor blockers improved the outcome of patients with severe COVID-19 and hypertension
por: Meng, Xiao, et al.
Publicado: (2020)

The Impact of Angiotensin-Converting Enzyme-2/Angiotensin 1-7 Axis in Establishing Severe COVID-19 Consequences
por: Maranduca, Minela Aida, et al.
Publicado: (2022)

Ethnic Prevalence of Angiotensin-Converting Enzyme Deletion (D) Polymorphism and COVID-19 Risk: Rationale for Use of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers
por: Sarangarajan, Rangaprasad, et al.
Publicado: (2020)

The association of COVID-19 occurrence and severity with the use of angiotensin converting enzyme inhibitors or angiotensin-II receptor blockers in patients with hypertension
por: Li, Mingfei, et al.
Publicado: (2021)

Urinary angiotensin-converting enzyme 2 and metabolomics in COVID-19-mediated kidney injury
por: Vergara, Ander, et al.
Publicado: (2022)

Angiotensin converting enzyme-2 as therapeutic target in COVID-19
por: Roshanravan, Neda, et al.
Publicado: (2020)

Angiotensin-converting enzyme 2 and COVID-19 in cardiorenal diseases
por: Sharma, Ravindra K., et al.
Publicado: (2021)

Angiotensin Converting Enzyme 2 - at the Heart of the COVID-19 pandemic
por: Oudit, Gavin Y., et al.
Publicado: (2023)

Rationale and design of “Can Very Low Dose Rivaroxaban (VLDR) in addition to dual antiplatelet therapy improve thrombotic status in acute coronary syndrome (VaLiDate-R)” study: A randomised trial modulating endogenous fibrinolysis in patients with acute coronary syndrome
por: Gue, Ying X., et al.
Publicado: (2019)

Angiotensin-Converting Enzyme 2 and the Resolution of Inflammation: In Support of Continuation of Prescribed Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers
por: Gersh, Felice L.
Publicado: (2020)

Angiotensin-Converting Enzyme Inhibitors and Angioedema
por: Sánchez-Borges, Mario, et al.
Publicado: (2010)

Angiotensin-converting Enzyme Genetic Polymorphism
por: Wiwanitkit, Somsri, et al.
Publicado: (2014)

Angiotensin-Converting-Enzyme 2 and Renin-Angiotensin System Inhibitors in COVID-19: An Update
por: Shukla, Ashwin Kumar, et al.
Publicado: (2021)

Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Blockers With Severity of COVID-19: A Multicenter, Prospective Study
por: Hakeam, Hakeam A., et al.
Publicado: (2020)

An observed association between angiotensin-converting enzyme 2 polymorphisms and COVID-19 severity in China
por: Wang, Jin, et al.
Publicado: (2022)

In reply—Angiotensin-Converting Enzyme 2 and the Resolution of Inflammation: In Support of Continuation of Prescribed Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers
por: Sanchis-Gomar, Fabian, et al.
Publicado: (2020)

Renin‐angiotensin aldosterone profile before and after angiotensin‐converting enzyme‐inhibitor administration in dogs with angiotensin‐converting enzyme gene polymorphism
por: Adin, Darcy, et al.
Publicado: (2020)

Role of angiotensin converting enzyme and angiotensinogen gene polymorphisms in angiotensin converting enzyme inhibitor-mediated antiproteinuric action in type 2 diabetic nephropathy patients
por: Aggarwal, Neerja, et al.
Publicado: (2017)

Angiotensin-converting enzyme-1 gene insertion/deletion polymorphism may be associated with COVID-19 clinical severity: a prospective cohort study
por: Gunal, Ozgur, et al.
Publicado: (2021)

Catheter ablation for AF improves global thrombotic profile and enhances fibrinolysis
por: Niespialowska-Steuden, Maria, et al.
Publicado: (2017)

Intrarenal Distributions and Changes of Angiotensin-Converting Enzyme and Angiotensin-Converting Enzyme 2 in Feline and Canine Chronic Kidney Disease
por: MITANI, Sawane, et al.
Publicado: (2013)

Relating angiotensin‐converting enzyme inhibitors or angiotensin receptor blockers with incidence or mortality of COVID‐19
por: Wong, Martin C.S., et al.
Publicado: (2020)

The controversy of using angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in COVID-19 patients
por: Harky, Amer, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_jel9vlj56vroimg2cu1j2cijvu